Pure Global AI
NCT06281132Not yet recruiting

Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D956 in Healthy Adults

A Randomized, Open-label, Single Dose, 4-period Replicate Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-341 in Healthy Volunteers Under Fasting Conditions
Chong Kun Dang PharmaceuticalPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Hypertension
Drug/Device/Intervention
CKD-341, D956
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chong Kun Dang Pharmaceutical
Location
Jeonju, South Korea
Timeline & enrollment
Phase
Phase 1
Start date
Mar 23, 2024
End date
May 14, 2024
Enrollment
48 participants
Primary outcome

area under curve(AUC) of CKD-341, D956,Cmax of CKD-341, D956

Summary

The objective was to evaluate and compare the pharmacokinetic profiles and safety after
 administration of test drug (CKD-341) and reference drugs (D956) in healthy adults.

ICD-10 classifications
Hypertensive diseasesRenovascular hypertensionSecondary hypertensionOther secondary hypertensionHypertensive heart disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06281132
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06281132 through Pure Global AI's free database. This Phase 1 trial is sponsored by Chong Kun Dang Pharmaceutical and is currently Not yet recruiting. The study focuses on Hypertension. Target enrollment is 48 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.